Edwards Lifesciences Corporation (E1WL34.SA)
São Paulo - São Paulo Delayed price. Currency in BRL
Add to watchlist
At close: 04:12PM BRT
| Previous close | 117.78 |
| Open | 116.90 |
| Bid | 116.96 x N/A |
| Ask | 117.45 x N/A |
| Day's range | 116.90 - 116.90 |
| 52-week range | 76.40 - 120.12 |
| Volume | |
| Avg. volume | 13 |
| Market cap | 282.183B |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | 9.39 |
| EPS (TTM) | 12.45 |
| Earnings date | 24 July 2024 - 29 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksHOLX vs. EW: Which Stock Should Value Investors Buy Now?
HOLX vs. EW: Which Stock Is the Better Value Option?
ZacksBD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite
BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.
Business WireFive-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR
NEW YORK, June 05, 2024--Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient’s annulus size or sex. These data were presented during the late-breaking clinical
© 2024 Yahoo. All rights reserved.